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Abstract
Background: Accumulating evidence suggests that myeloperoxidase (MPO) is involved in atrial remodeling of atrial
fibrillation (AF). Statins could reduce the MPO levels in patients with cardiovascular diseases. This study evaluated
the effects of atorvastatin on MPO level and atrial remodeling in a rabbit model of pacing-induced AF.
Methods: Eighteen rabbits were randomly divided into sham, control and atorvastatin groups. Rabbits in the
control and atorvastatin groups were subjected to rapid atrial pacing (RAP) at 600 bpm for 3 weeks, and treated
with placebo or atorvastatin (2.5 mg/kg/d), respectively. Rabbits in the sham group did not receive RAP. After
3 weeks of pacing, atrial structural and functional changes were assessed by echocardiography, atrial effective
refractory period (AERP) and AF inducibility were measured by atrial electrophysiological examination, and
histological changes were evaluated by Masson trichrome-staining. The L-type calcium channel α1c (Cav1.2),
collagen I and III, MPO, matrix metalloproteinase (MMP)-2 and MMP-9 were analyzed by real time polymerase chain
reaction and/or western blot.
Results: All rabbits were found to have maintained sinus rhythm after 3 weeks of RAP. Atrial burst stimulation
induced sustained AF (>30 min) in 5, 4, and no rabbits in the control, atorvastatin, and sham groups, respectively.
The AERP shortened and Cav1.2 mRNA level decreased in the control group, but these changes were suppressed in
the atorvastatin group. Obvious left atrial enlargement and dysfunction was found in both control and atorvastatin
groups. Compared with the control group, these echocardiograhic indices of left atrium did not differ in the
atorvastatin group. Prominent atrial fibrosis and increased levels of collagen I and III were observed in the control
group but not in the atorvastatin group. The mRNA and protein levels of MPO, MMP-2 and MMP-9 significantly
increased in the control group, but these changes were prevented in the atorvastatin group.
Conclusion: Treatment with atorvastatin prevented atrial remodeling in a rabbit model of RAP-induced AF. The
reduction of levels of atrial MPO, MMP-2 and MMP-9 may contribute to the prevention of atorvastatin on atrial
remodeling.
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Background
Atrial fibrillation (AF) is the most common sustained
arrhythmia in clinical practice, increasing in prevalence
with age [1]. It results in serious potential complications,
especially stroke and heart failure, and increased mortality
[2]. Despite recent advances in pharmacological strategy
and radiofrequency ablation, the treatment of AF is still
not satisfactory.
In recent years, accumulating evidence suggests that
the main mechanisms contributing to the initiation and
maintenance of AF are atrial electrical and structural re-
modeling [3, 4], and myeloperoxidase (MPO) is involved
in the associated atrial remodeling [5, 6]. MPO is a
major contributor to inflammatory oxidative stress, and
catalyzes the generation of reactive species [6]. It is a
crucial prerequisite for atrial fibrosis, leading to an in-
creased vulnerability to AF [5]. Patients with AF had higher
plasma and atrial MPO levels compared with individuals in
sinus rhythm [5], and high MPO level predicted an in-
creased risk of AF recurrence after catheter ablation [7].
Statins are widely used in primary and secondary pre-
vention of ischemic heart disease and stroke, because of
their lipid-lowering effect. In addition, statins also have
anti-inflammatory and antioxidant properties, which
may help prevent AF [8]. Recent meta-analyses showed
that the use of statins is associated with a decreased risk
of AF in patients with sinus rhythm [9, 10]. Some studies
also reported that statins could attenuate atrial electrical
or structural remodeling in dog and goat AF models
[11–14]. However, the molecular mechanism by which
statins may prevent AF has not been elucidated. Previ-
ous research showed that statins could reduce the MPO
levels in patients with cardiovascular diseases [15, 16].
This study was designed to investigate the potential ef-
fects of atorvastatin on MPO level and atrial remodeling
in a rabbit model of pacing-induced AF.
Methods
Animal preparation
Eighteen male New Zealand white rabbits (2.5–3.0 kg)
were randomly allocated to sham (n = 6), control (n = 6)
and atorvastatin (n = 6) groups. All rabbits were anesthe-
tized with an intravenous injection of 3 % pentobarbital
sodium (30 mg/kg). The left thoracic cavity was opened
via 2–4 intercostals, and then the heart was exposed by
a dilator. One thin silicon plaque containing two pairs of
electrodes was implanted in the free wall of the left atrial
appendage. One pair was connected to a pacemaker
(Fudan University, Shanghai, China) implanted in a sub-
cutaneous pocket on the back of the rabbit. The other
pair was tunneled subcutaneously and exposed at the
back of the rabbit, and used for electrophysiological
measurements [17]. When surgery was completed, rab-
bits were given antibiotics and allowed to recover for
one week. After that, rabbits in the control and atorva-
statin groups were subjected to rapid atrial pacing (RAP)
at 600 beats/min for 3 weeks, meanwhile they received
oral placebo or atorvastatin (2.5 mg/kg/day), respect-
ively. Rabbits in the sham group did not receive RAP.
Electrophysiological study
Electrocardiogram (ECG) was recorded before and after
the pacing. During the period of RAP, ECG was mea-
sured every day to ensure that the pacemakers were
working properly.
The atrial effective refractory period (AERP) was mea-
sured at a basic cycle length of 150 ms. Eight basic stim-
uli (S1) were followed by a premature stimulus (S2). The
S1-S2 intervals were decreased in 10 ms steps until S2
failed to produce an atrial response, then increased by
10 ms, and decreased in 2 ms steps until S2 capture
failure. The longest S1-S2 interval that failed to capture
was defined as the AERP150 [11, 17].
AF was induced with a train of 10Hz, 2 ms stimuli to
the left atrium at four times threshold current [17] and
was induced ten times in each rabbit. AF was considered
sustained if it persisted for more than 30 min.
Echocardiography
The structure and function of the left atrium (LA) and
left ventricle (LV) were assessed by transthoracic echo-
cardiographic examinations (Philips IU 22, Washington,
USA). LV end diastolic diameter (LVEDD) and end sys-
tolic diameter (LVESD), LV ejection fraction (LVEF), LA
diameter (LAD), LA maximal volume (LAVmax) and
minimal volume (LAVmin) were measured before and
after the pacing. The volume measurements were calcu-
lated from apical 4- and 2-chamber views using the bi-
plane area-length method. LAVmax was recorded
immediately before the mitral valve opening and LAVmin
was recorded at mitral valve closure. LA ejection frac-
tion (LAEF) was calculated according to the formula:
(LAVmax- LAVmin)/LAVmax × 100 % [18].
Histological examination
At the end of the experiments, all rabbits were eutha-
nized and then the LA free wall tissues were quickly re-
moved. Formalin-fixed paraffin-embedded tissues were
stained with Masson’s trichrome. The collagen fibers
were marked with blue, while the cardiomyocytes were
marked with red. Fibrous tissue areas were quantified
using Image Pro Plus 6.0 software (Media Cybernetics,
Maryland, USA) [19].
Western blot analysis
The total proteins were purified from the LA free wall,
separated by 10 % SDS-PAGE, and then transferred onto
a polyvinylidene difluoride membrane. This was blocked
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at room temperature for 1 h in Tris-buffered saline with
0.5 % Tween 20 containing 5 % skim milk and probed
with primary antibodies overnight at 4 °C.
The following primary antibodies were independently
used to detect specific proteins: collagen I (1:500 dilution,
Bioworld, USA), collagen III (1:500 dilution, Bioworld,
USA), MPO (1:200 dilution, Santa Cruz, USA), matrix
metalloproteinase (MMP)-2 (1:500 dilution, ProteinTech,
USA), MMP-9 (1:500 dilution, ProteinTech, USA), and
tissue inhibitors of metalloproteinase (TIMP)-1 (1:1000
dilution, Abcam, USA). An antibody against β-actin
(1:1000 dilution, ProteinTech, USA) was used as an in-
ternal control.
Horseradish peroxidase-conjugated anti-goat (1:10000
dilution, Beyotime, China) or anti-mouse (1:10000 dilu-
tion, ZSGB Biological Company, China) IgGs were used
to bind the primary antibodies. Protein bands on Western
blots were visualized using an enhanced chemilumines-
cence detection system (Santa Cruz, USA). Relative band
densities of proteins in Western blots were normalized
against β-actin.
Real time polymerase chain reaction (RT-PCR)
Total RNA was extracted with TRIZOL reagent (Invitro-
gen, USA). In accordance with the protocol provided by
the manufacturer, cDNA was synthesized with an
EasyScript First-Strand cDNA Synthesis Kit (TransGen
Biotech, China). Quantitative RT-PCR was performed with
Maxima™ SYBR Green qPCR Master Mix (Fermentas,
USA) on an ABI7500 real-time PCR system (Applied Bio-
systems, USA). Glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) was used for control of internal gene
expression. The primers for GAPDH, L-type calcium
channel α1c (Cav1.2), transient outward potassium chan-
nel (Kv4.3), MPO, MMP-2, MMP-9 and TIMP-1 are
shown in Table 1.
Statistical analysis
Quantitative data are expressed as mean ± standard devi-
ation. Comparisons of data before and after RAP were
analyzed by t-test. Multiple-group comparisons were
analyzed using one-way analysis of variance. SPSS 19.0
software (IBM-SPSS, Chicago, USA) was used in the




Conventional ECGs were recorded in anesthetized intact
rabbits (Fig. 1a). It is clear that 3 weeks of RAP did not
cause AF, because when the pacemakers were deacti-
vated, ECGs confirmed sinus rhythm in each rabbit in
the control and atorvastatin groups.
Atrial burst stimulation induced sustained AF in 5 out
of 6 (83 %) rabbits in the control group, 4 of 6 (67 %) in
the atorvastatin group, but none in the sham group
(Fig. 1b).
Before RAP, no significant difference in the AERP150
was observed among the 3 groups (sham group: 104 ms ±
5 ms, control group: 105 ms ± 5 ms, atorvastatin group:
103 ms ± 4 ms). After 3 weeks of RAP, the AERP150 of the
control group (76 ± 4 ms) was significantly shorter than
that of the sham group (103 ± 4 ms, P < 0.05). The
AERP150 of the atorvastatin group was also shortened
(85 ± 5 ms), but the RAP-induced reduction was re-
versed to some extent compare with the control group
(76 ± 4 ms, P < 0.05) (Fig. 1c).
Echocardiographic characteristics
Echocardiography was performed before and after RAP
(Table 2). After 3 weeks of RAP, obvious LA enlarge-
ment and dysfunction was observed, but no changes in
LV diameter and function were found. In the control
and atorvastatin group, LAD, LAVmax and LAVmin sig-
nificantly increased, whereas LAEF dramatically de-
creased after 3 weeks of RAP. Compared with the
control group, these echocardiographic indices of LA
did not differ in the atorvastatin group.
Atrial structural remodeling
As shown in Fig. 2, RAP caused a marked LA interstitial
fibrosis as estimated by Masson trichrome-staining. The
Table 1 RNA primer sequences








GAPDH glyceraldehyde-3-phosphate dehydrogenase, Cav1.2 L-type calcium channel α1c, Kv4.3 transient outward potassium channel, MPO myeloperoxidase, MMP
matrix metalloproteinase, TIMP tissue inhibitors of metalloproteinase
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Fig. 1 Changes in electrophysiological characteristics. a Representative surface ECG recordings during RAP (a), after RAP (b) and after atrial burst
pacing (c) (paper speed 50 mm/s). a. ECG recordings in limb leads during RAP at 600 beats/min. b. ECG recordings in limb leads showed that the
rabbit was still in normal sinus rhythm after 3 weeks of RAP when the pacemaker was deactivated. c. ECG recordings in limb leads showed that
after atrial burst pacing, the rabbit was induced AF: disappearance of P-wave, and absolute irregularity of the RR interval. b AF inducibility in the
sham, control and atorvastatin groups. c Comparison of AERP150 among the 3 groups, each bar represents the means ± standard deviation. ECG:
electrocardiogram; RAP: rapid atrial pacing; AF: atrial fibrillation; AERP150: atrial effective refractory period at a basic cycle length of 150 ms.
*P < 0.05 vs. sham group; #P < 0.05 vs. control group
Table 2 Changes of echocardiographic indices before and after RAP
LAD (mm) LAVmax (ml) LAVmin (ml) LAEF (%) LVESD (mm) LVEDD(mm) LVEF (%)
Sham group
Baseline 9.73 ± 0.69 0.54 ± 0.08 0.27 ± 0.05 48.82 ± 4.48 8.46 ± 0.99 13.68 ± 1.77 72.20 ± 3.65
4 weeks post-operation 9.85 ± 0.61 0.53 ± 0.07 0.28 ± 0.05 47.59 ± 6.05 8.44 ± 0.91 13.53 ± 1.53 71.75 ± 2.81
Control group
Baseline 9.58 ± 0.62 0.52 ± 0.09 0.26 ± 0.03 49.42 ± 3.39 8.39 ± 0.88 13.37 ± 1.23 71.18 ± 4.46
3 weeks after RAP 16.02 ± 0.84*, ** 1.94 ± 0.28*, ** 1.40 ± 0.18*, ** 27.77 ± 4.18*, ** 8.77 ± 0.64 13.35 ± 1.28 67.47 ± 2.92
Atorvastatin group
Baseline 9.75 ± 0.56 0.55 ± 0.10 0.28 ± 0.05 49.31 ± 5.48 8.37 ± 0.94 13.58 ± 1.32 71.42 ± 3.15
3 weeks after RAP 15.53 ± 0.62*, ** 1.78 ± 0.24*, ** 1.29 ± 0.17*, ** 27.32 ± 3.70*, ** 8.78 ± 0.78 13.64 ± 1.22 68.50 ± 5.34
Data are reported as mean ± standard deviation
RAP rapid atrial pacing, LAD left atrial diameter, LAVmax left atrial maximal volume, LAVmin left atrial minimal volume, LAEF left atrial ejection fraction, LVESD left
ventricular end systolic diameter, LVEDD left ventricular end diastolic diameter, LVEF left ventricular ejection fraction
*P < 0.05 vs. baseline
**P < 0.05 vs. sham group
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degree of atrial fibrosis in the control and atorvastatin
group was significantly higher than that in the sham
group. Compared with the control group, the atrial fi-
brosis was partial suppressed in the atorvastatin group.
As shown in Fig. 3, the protein levels of collagen I and
collagen III were significantly increased in the control
group in comparison with the sham group. These
changes in the levels of these 2 types of collagen were
suppressed by atorvastatin.
Atrial ion-channel remodeling
As shown in Fig. 4, the Cav1.2 mRNA significantly de-
creased in the control group compared with the sham
group, but it down-regulation was prevented in the ator-
vastatin group. The Kv4.3 mRNA was also significantly
decreased in the control group compared to the sham
group, but it down-regulation was not prevented in the
atorvastatin group.
Levels of MPO, MMP-2, MMP-9 and TIMP-1 in the LA
As shown in Fig. 5, the mRNA and protein levels of
MPO, MMP-2 and MMP-9 were significantly increased
in the control group compared with the sham group.
These changes in the levels of MPO, MMP-2 and MMP-9
were suppressed by atorvastatin. The level of TIMP-1 was
also increased in the control group compared to the sham
group, but atorvastatin treatment did not suppress the up-
regulation of TIMP-1.
Discussion
The present data demonstrated that in the rabbit model
of RAP-induced AF, atorvastatin suppressed AERP
shortening and atrial interstitial fibrosis induced by RAP,
but had no effect on RAP-induced atrial enlargement
and dysfunction. In addition, atorvastatin suppressed the
down-regulation of Cav1.2 mRNA, and prevented the in-
crease in the levels of collagen I and III, MPO, MMP-2
and MMP-9 induced by RAP.
The main mechanisms contributing to AF initiation
and maintenance are atrial electrical and structural re-
modeling. In recent years, several animal models of AF
[11–13, 20, 21] have been developed to investigate the
molecular mechanism contributing to atrial remodeling.
Among them, the dog [11, 14, 20] and rabbit [17, 19, 21]
Fig. 2 Histological analysis of atrial interstitial fibrosis. a Representative Masson trichrome-staining of left atrial myocardium in the sham (a), control (b)
and atorvastatin (c) groups (The magnification is × 200, scale bar: 50um). b Percentage of areas of interstitial fibrous tissue among the 3 groups, each
bar represents the means ± standard deviation. *P < 0.05 vs. sham group; #P < 0.05 vs. control group
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AF models induced by RAP are widely used. However, if
atrioventricular block is not performed, dogs will de-
velop significant LV dysfunction induced by RAP [20],
whereas rabbits will not [21]. It is well known that LV
dysfunction will subject the LA to a pressure overload,
leading to atrial enlargement and electrical instability
[22]. Therefore, in the present study we chose rabbits to
create an AF animal model to avoid the influence of LV
dysfunction on atrial remodeling.
Effects of atorvastatin on atrial structural remodeling
Atrial structural remodeling is characterized by atrial en-
largement and interstitial fibrosis [4, 23], and has been
considered as a major contributor to AF [23]. LA en-
largement has been identified as an independent risk
factor for AF. For example, patients are more prone to
paroxysmal AF if they have an increased LAD [24]. Lar-
ger LA volume before cardioversion is associated with
higher risks of AF recurrence [25]. LA enlargement also
significantly correlates with atrial fibrosis, which serves
as a crucial substrate in the formation of AF and is diffi-
cult to reverse [26]. Increased fibrosis has been observed
in the atrium of animal models [20, 21] and patients
with AF [27]. It is characterized by enhanced deposition
of matrix collagen proteins, leads to inhomogeneous
atrial electrical conduction, and gives rise to electrical
reentry circuits which result in AF [6].
In our study, after 3 weeks of RAP, rabbits showed sig-
nificant atrial structural remodeling. The pacing time of
our rabbit AF model is relatively short compared with
the previous canine AF model [14, 20], but rabbits have
already had obvious atrial enlargement and interstitial fi-
brosis. In the previous canine AF model, after 4–6 weeks
of RAP, LA volumes were nearly 2 times that at baseline
[14, 28], and atrial fibrosis of the control group was
nearly 9–10 times that of the sham group [20, 28]. In
Fig. 3 The protein levels of collagen I and collagen III in the left atrium. a Representative western blot gels depict the protein expression levels of
collagen I and collagen III. b Mean values of the protein expression levels of collagen I and collagen III in the 3 groups. Each bar represents the
means ± standard deviation. *P < 0.05 vs. sham group; #P < 0.05 vs. control group
Fig. 4 The mRNA levels of Cav1.2 and Kv4.3 in the left atrium. Each
bar represents the means ± standard deviation. Cav1.2: L-type calcium
channel α1c; Kv4.3: transient outward potassium channel; mRNA: micro
ribonucleic acid. *P < 0.05 vs. sham group; #P < 0.05 vs. control group
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our model, after 3 weeks of RAP, LA volumes were
nearly 4 times that at baseline, and atrial fibrosis of the
control group was nearly 7 times that of the sham group.
The obvious atrial structural remodeling contributed to
a marked increase in AF inducibility. After 3 weeks of
RAP, although all rabbits in the control group remained
sinus rhythm when pacemakers were deactivated, atrial
burst pacing induced sustained AF almost in all rabbits.
Our study showed that atorvastatin treatment could
not prevent AF susceptibility and atrial enlargement and
dysfunction, but could prevent atrial interstitial fibrosis
and collagen protein expression levels. These results are
not completely consistent with the previous research
[14], which showed that statins could not prevent AF
susceptibility, but could prevent atrial dilatation and fi-
brosis in a canine AF model induced by 6 weeks of RAP.
The different effects of statins on atrial dilatation may be
attributed to different AF animal models and drug inter-
vention time. In addition, LA volumes after RAP were
only 2 times that at baseline in the previous research,
while in our study these were nearly 4 times that at base-
line, which may predict more serious LA enlargement, so
is hard to reverse.
The metabolism of extracellular matrix is regulated by
MMPs and their inhibitors, the TIMPs [29]. Among
many kinds of MMPs and TIMPs, MMP-2 and MMP-9
are key factors leading to atrial fibrosis in AF [5, 30, 31],
while TIMP-1 is a major inhibitor of MMP activity in
AF tissues [31]. MPO, a major contributor to inflamma-
tory oxidative stress, also has an important role in AF. It
could promote MMP expression and activation by cata-
lyzing the generation of reactive species, and subse-
quently resulted in atrial fibrosis and AF [5, 6]. Previous
research showed that patients with AF had higher
plasma and atrial MPO levels compared with individuals
in sinus rhythm [5], and high MPO levels predicted an
increased risk of AF recurrence after catheter ablation
[7]. In addition, MPO-deficient mice were protected
from atrial fibrosis and AF vulnerability induced by
angiotensin II, and atrial MMP-2 and MMP-9 levels
were profoundly reduced. However, if administrated with
recombinant MPO, these MPO-deficient mice would de-
velop a similar degree of atrial fibrosis as that observed
in MPO-infused wild type mice [5].
Many studies showed that statins, by their anti-
inflammatory and antioxidant properties, could reduce
the levels of plasma MPO in patients with cardiovascular
diseases [15, 16], and inhibit MPO mRNA expression in
macrophages [32]. In addition, statins also could inhibit
secretion of MMP-2 and MMP-9 [33], and down-
regulate their expression levels [34, 35]. In our study, the
levels of MPO, MMP-2, MMP-9 and TIMP-1 were sig-
nificantly increased after RAP. Atorvastatin treatment
could suppress the increased levels of MPO, MMP-2
and MMP-9, especially MPO and MMP-9, but could not
suppress the increased level of TIMP-1. These may be
the potential mechanisms by which statins prevent atrial
structural remodeling of AF.
In addition, peroxisome proliferator-activated receptor-
gamma (PPARγ) is also involved in atrial remodeling and
AF. Recent studies showed that PPARγ was decreased in
elderly AF patients [36] and hypertensive AF patients [37],
while PPARγ agonists could inhibit atrial remodeling in
AF models [38, 39] and prevent new onset AF in patients
with non-insulin dependent diabetes [40]. Statins could
activate PPARγ and enhance its expression [41, 42] by
Fig. 5 The levels of MPO, MMP-2, MMP-9 and TIMP-1 in the left
atrium. a Mean values of the mRNA expression levels of MPO, MMP-2,
MMP-9 and TIMP-1 in the 3 groups. b Representative western blot gels
depict the protein expression levels of MPO, MMP-2, MMP-9 and
TIMP-1. c Mean values of the protein expression levels of MPO,
MMP-2, MMP-9 and TIMP-1 in the 3 groups. Each bar represents
the means ± standard deviation. mRNA: micro ribonucleic acid; MPO:
myeloperoxidase; MMP: matrix metalloproteinase; TIMP: tissue
inhibitors of metalloproteinase. *P < 0.05 vs. sham group; #P < 0.05 vs.
control group
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their anti-inflammatory and antioxidant properties.
Therefore, whether the modulation of statins on
PPARγ is involved in the molecular mechanisms of
the prevention of statins against atrial remodeling in
our rabbit model of AF is still a question and would
be investigated in our future study.
Effects of atorvastatin on atrial electrical remodeling
Atrial electrical remodeling is characterized by ion channel
dysfunction [4], which creates a re-entry-prone substrate.
In our study, 3 weeks of RAP caused AERP shortening and
down-regulation of Cav1.2 and Kv4.3 mRNA. This is
consistent with previous research using dog AF
models [11, 20, 21]. In the present study, atorvastatin
treatment could partially suppress AERP shortening
and Cav1.2 mRNA down-regulation, but had no effect
on Kv4.3 mRNA down-regulation. Many studies have
proved that atrial electrical remodeling was promoted
by inflammation and oxidative stress, while could be
reversed by statins [8, 11, 13, 43]. As mentioned above,
atorvastatin treatment suppressed the increased level of
MPO, which is a major contributor to inflammatory oxi-
dative stress. Therefore, our study suggests that statins
may prevent electrical remodeling, and the reduced atrial
MPO level may contribute to the prevention of statins on
this process.
Conclusion
The present study demonstrated that atorvastatin treat-
ment prevented atrial remodeling in a rabbit model of
RAP-induced AF. The reduction of levels of atrial MPO,
MMP-2 and MMP-9 may contribute to the prevention
of atorvastatin on atrial remodeling. These findings
provide pharmacological evidence for the clinical use
of statins in the treatment of AF.
Limitations
The sample size was relatively small, and the duration of
RAP was relatively short. In this study, we only mea-
sured the levels of MPO, MMP-2 and MMP-9, but did
not measure their enzymatic activity in the atrium. In
addition, we did not investigate whether the preventive
effects of atorvastatin on atrial remodeling of AF were
dose-dependent, and did not conduct detailed molecular
study in cardiac tissue as well as extracellular matrix re-
modeling due to some methodological limitations. Last
but importantly, we did not show the causality between
the inhibition of MPO by statins and the suppressed
atrial remodeling. MPO might be just a concomitantly
induced factor rather than a key mediator in our model.
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